



Current and emerging concepts in atopic dermatitis pathogenesis

Marguerite Sullivan, MD^a, Nanette B. Silverberg, MD^{b,*}

^aDepartment of Dermatology, Mt. Sinai St Luke's–Roosevelt Hospital Center, New York, NY

^bIcahn School of Medicine at Mt. Sinai St Luke's–Roosevelt Hospital Center, New York, NY

Abstract Atopic dermatitis is a common skin disorder with a complex, evolving pathogenesis. Research on the pathogenesis has shifted from focusing primarily on generalized immune system abnormalities in T helper 1/T helper 2 (T_H1/T_H2) activity to more targeted immune and skin barrier abnormalities contributing to the overall phenotype. Specific signaling pathways recently implicated in atopic dermatitis include production of interleukin (IL) 4 and IL-13, which promote immunoglobulin E production, T_H17 and T_H22 cells, and production of cytokines. Barrier defect abnormalities, such as a shared filaggrin mutation noted in ichthyosis vulgaris and atopic dermatitis, as well as reduced structural proteins and lipids (eg, ceramides), have been discovered as well. These alterations contribute to increased transepidermal water loss in addition to increased allergen exposure, resulting in debate over the “inside out” versus “outside in” theories—that is, the concept that immunity triggers barrier breakdown versus barrier abnormalities triggering immunologic alteration toward atopy. In fact, it is likely that all of these contribute to pathogenesis, with some individuals initially experiencing immunologic abnormalities more strongly than barrier defects and vice versa. Genetic analyses have continued to advance, leading to the discovery of potential candidate genes relating both to the impaired skin barrier and the altered immune system pathways. This review outlines the evolution of the field of current pathogenesis of atopic dermatitis, highlighting the most pertinent recent findings.

© 2017 Elsevier Inc. All rights reserved.

Introduction

Atopic dermatitis (AD) is a chronic, pruritic skin disorder that begins largely in childhood, continuing or occasionally beginning in adults worldwide with increasing prevalence over the past 30 years.¹ Cumulative incidence suggests about one-quarter to one-third of individuals will be affected in the United States. The 1-year prevalence of AD in the United States of approximately 10.7% of children in 2003–2004 and

13.0% of children in 2007–2008 has been reported, with the largest prevalence occurring in metropolitan areas and regions with lower humidity, lower temperatures, and lower UV indices.^{2–6} Skin manifestations and site of involvement vary by age and range from weeping papulovesicles to lichenified plaques⁷ initially affecting extensor surfaces, and later shifting to flexural surfaces and hands. Approximately 60% of childhood cases begin in the first year of life, with nearly 85% beginning by age 5 years.⁸ There is a slight female-to-male predominance,⁹ and approximately 70% of patients have a family history of atopic diseases, such as AD, asthma, or allergic rhinitis.¹⁰

The pathogenesis of AD is multifactorial, involving a complex interaction of genetic and environmental factors. Concordance rates among monozygotic twins was found to be 77%,

* Corresponding author. Nanette B. Silverberg, MD, Clinical Professor of Dermatology and Pediatrics, Mt. Sinai St. Luke's–Roosevelt Hospital, 1090 Amsterdam Avenue, Suite 11B, New York, NY 10025. Tel. (212) 523-3888. E-mail address: nanette.silverberg@mountsinai.org (N.B. Silverberg).

compared with 15% for dizygotic twins, supporting a strong genetic contribution to disease development.¹¹ The original model of AD pathogenesis attributed disease to an imbalance in cell-mediated T helper (T_H) 1 versus T_H2 response.¹² Theories on AD pathogenesis continue to evolve, with a recent focus on newer immunologic pathways and barrier-based abnormalities. Some have suggested that AD may be driven by elevated immunoglobulin E (IgE), similar to asthma and allergic rhinitis, which are commonly present in AD patients^{13–16}; however, recent research has uncovered significant contributions to AD pathogenesis by skin barrier impairment, additional inflammatory cell types, such as T_H9, T_H17, and T_H22, and broader cytokine profiles.^{17–19} The evolution of these components of AD pathogenesis has led to questioning the origin of disease and whether it is triggered by external or internal factors (ie, the outside in versus inside out hypotheses).²⁰

Impaired skin barrier

Focus on pathogenesis of AD has evolved from concentration on immune system dysfunction as the primary abnormality in disease development to incorporating the concept of epidermal barrier dysfunction.²¹ Impaired skin barrier may be the primary abnormality or trigger of disease onset in many individuals, but it can also occur secondary to cutaneous inflammation.²² Skin- and mucosal barrier-based abnormalities may also be the mechanisms by which cutaneous disease expands to food allergies, environmental allergies, and asthma (ie, the atopic march).²³

The stratum corneum is composed of corneocytes, which secrete intercellular substances (eg, filaggrin) that breakdown to substances including amino acids (ie, the natural moisturizing factor) and lipids (eg, ceramides), serving to create a barrier layer protecting the epidermis against environmental insults.²⁴ Numerous alterations and deficiencies in the proteins and lipids of the stratum corneum of atopic individuals have been implicated in the disturbed skin barrier, highlighting the importance of the skin barrier in disease development.^{21,25} Among these is a reduced content of hygroscopic and structural matrix materials that are believed to serve as important mediators in the pathogenesis of AD (eg, ceramides).²⁶ These epidermal alterations functionally appear as a key step in disease, because the stratum corneum in both affected and unaffected skin of patients with AD has altered barrier function, resulting in increased transepidermal water loss. AD patients manifest dry skin diffusely, even when the patient is not flaring.²⁷

Another factor altering the skin barrier is the presence of a common, underlying loss of function mutation of filaggrin (FLG) found in both ichthyosis vulgaris and AD.^{28–31} FLG is an epidermal protein that functions in combination with its breakdown products as a leading contributor to maintenance of hydration and homeostasis of the stratum corneum, particularly in response to a changing environment.³² The FLG loss-

of-function mutation is found in approximately 10% of the general population. Numerous reports have confirmed the predisposition of patients with ichthyosis vulgaris to the development of AD and asthma.³³ The discovery of this genetic predisposition for an impaired barrier provides a basis for the “outside in” hypothesis whereby the barrier triggers immunologic changes. Acquired reductions in filaggrin function have been reported even in the absence of a loss-of-function mutation, with reported triggers of environmental origin including low humidity and mechanical damage; triggers also include IL-4 and thymic stromal lymphopoietin (TSLP), and, to a lesser degree, IL-13, IL-17, IL-22, and IL-31.³⁴ IL-4 and IL-13 also stimulate B-cell production of IgE, which further promotes atopy. Keratinocyte products such as antimicrobial peptides can induce cytokines such as IL-4, IL-13, IL-25, IL-33 and TSLP.³⁵

The discovery of the connection between AD and FLG mutations has led to further research into barrier defects. FLG is located within the epidermal differentiation complex (EDC), which is a complex of several genes important in the maturation of the stratum corneum. These include S100 calcium binding proteins (S100s), the small proline-rich proteins (SPRRs), the late expressed cornified envelope proteins, trichohyalin, repetin, involucrin, loricrin, and filaggrin^{36–41} (Table 1).^{42–44} The discovery of the FLG gene in the EDC as well as the EDC’s importance in the creation of the epidermal barrier led to a screen of the EDC for mutations in which a repeat number variant in SPRR3 was discovered as another risk factor for eczema.⁴⁵

Abnormalities in T-cell and immune function

CD4⁺ helper T lymphocytes play an essential role in adaptive immunity. Once activated by cytokines from antigen-presenting cells, they differentiate into T_H1 and T_H2 lymphocytes. Th1 cells then secrete interferon (IFN) γ and IL-12 to promote destruction of intracellular pathogens while

Table 1 Components of the epidermal differentiation complex

Component	Association with disease
S100 calcium binding proteins (S100s)	Psoriasis (psoriasin-S100 A7)
Small proline-rich proteins (SPRRs)	Atopic dermatitis (SPRR3)
Late expressed cornified envelope proteins	
Trichohyalin	Atopic dermatitis (nonsense SNVs-TCHH [E207 X] and TCHHL1) ⁴²
Cornulin	Atopic dermatitis (missense variants) ⁴²
Hornulin	Atopic dermatitis (missense variants) ⁴²
Repetin	Atopic dermatitis (reduced expression) ⁴³
Involucrin	Atopic dermatitis ⁴⁴
Loricrin	Atopic dermatitis ⁴⁴
Filaggrin	Atopic dermatitis (nonsense variants in FLG1-Europe and FLG2-Ethiopia) ⁴²

simultaneously suppressing the T_H2 -mediated humoral immunity. A dominance of T_H2 cytokines is seen in lesions of AD; these include IL-4, IL-5, and IL-13, which promote the creation of IgE antibodies whose purpose is to destroy extracellular pathogens but which play a fundamental role in allergic responses.⁴⁶ Dupilumab, a fully human monoclonal antibody that binds to the shared α subunit of IL-4 and IL-13, has recently been reported to improve signs and symptoms of AD in phase 3 trials, confirming the significance of these cytokines in the pathogenesis of AD.⁴⁷ IL-4 and IL-13 are also known to affect lipid and defensin expression in the skin barrier unrelated to filaggrin defects, connecting the barrier defects directly to the immune system.⁴⁸ Abnormalities in cyclic AMP phosphodiesterase in AD were postulated to affect immune function of B and T cells and are currently the target of extensive therapeutic research.⁴⁹

A number of genes have been found that may contribute to this abnormal cytokine profile. A gene cluster on chromosome 5 q31-33, discovered through AD linkage analyses, was found to contain a number of gene polymorphisms that are thought to be potential candidates in the pathogenesis of AD. These genes encode IL-4, IL-13, T-cell immunoglobulin and mucin domain 1, and serine protease inhibitor Kazal type 5 (SPINK5).^{41,42} Loss-of-function mutations in serine protease inhibitors, such as SPINK5, which is associated with the autosomal recessive Netherton syndrome, augment pathways that enhance T_H2 responses^{41,48}; furthermore, single nucleotide polymorphisms have been found in the gene encoding IL-18, which is known to contribute to AD through the production of IL-4 and IL-13.^{50,51} Recently, a functional point mutation on chromosome 17 q11.2-q12 was discovered that leads to increased production of RANTES, a chemokine that promotes mobilization of memory T_H cells produced primarily in dermal fibroblasts, in AD.^{41,52} In real-world practice it is impossible to clinically identify the pathogenetic cause of any patient's AD.

A biphasic response of cell-mediated immunity has been implicated in the pathogenesis of AD lesions, with T_H2 cells increased in both the acute and chronic phases and T_H1 cells increased particularly in the chronic phase.⁵³ T_H2 cytokines not only promote antibody production and atopy, they also have been implicated in altering the differentiation of the epidermal barrier.⁵⁴ For example, expression of FLG was found to be increased by expression of T_H2 cytokines.⁵⁵ T_H1 response feeds the chronic inflammation and has been found to promote apoptosis of keratinocytes through interaction of IFN- γ with the Fas receptor.⁵⁶

There has been a recent paradigm cell types shift to implicate a broader array of cells and cytokines in AD pathogenesis. In acute lesions, T_H17 and T_H22 cytokines have been found to play a role in addition to T_H2 .⁵⁷ T_H17 cells have been found in increased levels both in the peripheral blood and acute lesions, with the percentage of cells correlating with the severity of the eczema. IL-17 serves to promote inflammation through stimulating keratinocytes to produce cytokines, such as granulocyte macrophage colony-stimulating factor, tumor necrosis factor α , IL-8, C x C motif chemokine ligand 10,

and vascular epidermal growth factor.¹⁹ CD8 cells have also been implicated in the production of IL-13 and IFN- γ in lesions of atopic dermatitis.⁵⁸ T_H17 cells have also been implicated in Asian patients with more psoriasiform lesions in AD, as well as psoriasis.⁵⁸

Interaction of the skin barrier and immune function

Both affected and unaffected skin in patients with AD is abnormal, with a chronic mild inflammation present even between flares.⁵⁹ In contrast to psoriasis, which has upregulation of antimicrobial peptides, AD skin has a reduced number,⁶⁰ thought to be attributed to increased expression of cytokines IL-4 and IL-13.⁶¹ This immunomodulation enables both increased colonization of *Staphylococcus aureus* and increased infections in the skin of patients with AD. It is postulated that *S aureus* further decreases the strength of the barrier through degradative serine proteases.⁶² Another interaction of the impaired skin barrier in AD includes production of TSLP by the barrier, resulting in attraction of inflammatory cells such as eosinophils.⁶³

Whether primary or secondary, the impaired skin barrier allows for increased antigen absorption or entry into the subcutaneous space, which contributes to sensitization and inflammation¹¹; however, it is unknown what leads to the initial inflammation that causes AD lesions. Skin lesions in atopic individuals typically precede IgE sensitization, and approximately 20% of patients have AD in the absence of other forms of atopy.^{21,64} It is hypothesized that dendritic cells are the linking factor between allergen exposure and subsequent inflammatory lesions.¹² Dendritic cells in patients with atopic dermatitis have increased high-affinity receptors for immunoglobulin E. Antigen and IgE-mediated binding to this receptor results in an inflammatory cascade, as the antigen-presenting dendritic cell both interacts with T lymphocytes and produces chemokines to attract additional lymphocytes to the area.^{65,66} As a result, the impaired skin barrier allows for allergen exposure, which subsequently drives dendritic cells to release cytokines promoting T_H2 cell differentiation.^{67,68} Keratinocytes contribute through production of TSLP, which further stimulates dendritic cells and drives the T_H2 response.⁶⁹ Cytokines produced by T_H2 cells then contribute to the impaired barrier through inhibiting maturation of the stratum corneum, perpetuating a vicious cycle of damage.⁵⁴

Ongoing research

Though a number of cytokines have been implicated in the pathogenesis of AD, their contribution will ultimately be determined by the efficacy of therapeutic modalities that target these molecules. IL-17 has been found to be a contributor in the pathogenesis, and studies are underway to determine if

blocking this cytokine will be as effective in AD as it has proven to be in psoriasis. Inhibiting IL-4 and IL-13 has also proven to be efficacious, but results of long-term studies are pending.⁴⁷ Additional research targeting IL-13, IL-17, phosphodiesterase, and TSLP ligand will help to determine the pathogenic contribution of these. Further research into the EDC, such as the SPRR3 gene variant, will be needed to further define its role in the pathogenesis. Similarly, genome-wide association studies and high-throughput expression profiling are underway to uncover relevant gene polymorphisms further contributing to the barrier defect.⁷⁰

Conclusions

Our understanding of the complex multifactorial pathogenesis of AD is evolving. T_H2 inflammation plays a primary role, as well as T_H1 , T_H17 , and T_H22 pathways; additional cytokines; the impaired skin barrier; and associated genetic polymorphisms. Whether “inside-out” or “outside-in,” altered skin barrier plays a significant role through increased allergen exposure, increased transepidermal water loss, and a cellular environment that promotes inflammation. The inflammatory cascade, whether a primary or secondary component of the disease process, contributes to the impaired skin barrier through inhibiting differentiation of the epidermis. Though there have been significant developments in the pathogenesis of AD, the picture is still missing some key components. Continued advances in pathogenesis and therefore therapy will significantly affect the lives of a large number of children and adults worldwide.

References

- Asher M, Montefort S, Björkstén B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phase one and three repeat multicountry cross-sectional surveys. *Lancet*. 2006;368:733-743.
- Shaw T, Currie G, Koudelka C, et al. Eczema prevalence in the United States: Data from the 2003 National Survey of Children's Health. *J Invest Dermatol*. 2011;131:67.
- Keeley DJ, Neill P, Gallivan S. Comparison of the prevalence of reversible airways obstruction in rural and urban Zimbabwean children. *Thorax*. 1991;46:549-553.
- Addo Yobo EO, Custovic A, Taggart SC, et al. Exercise induced bronchospasm in Ghana: Differences in prevalence between urban and rural school-children. *Thorax*. 1997;52:161-165.
- Yemaneberhan H, Bekele Z, Venn A, et al. Prevalence of wheeze and asthma and relation to atopy in urban and rural Ethiopia. *Lancet*. 1997;350:85-90.
- Silverberg J, Hanifin J, Simpson E. Climatic factors are associated with childhood eczema prevalence in the United States. *J Invest Dermatol*. 2013;133:1752-1759.
- Rudikoff D, Lebowitz M. Atopic dermatitis. *Lancet*. 1998;351:1715.
- Kay J, Gawkrödger DJ, Mortimer MJ, et al. The prevalence of childhood atopic eczema in a general population. *J Am Acad Dermatol*. 1994;30:35-39.
- Kang K, Polster AM, Nedorost S, et al. Atopic dermatitis. In: Bologna JL, Jorizzo JL, Rapini RP, et al, eds. *Dermatology*. New York, NY: Mosby; 2003. p. 199.
- Eichenfield L, Tom W, Chamlin S, et al. Guidelines of care for the management of atopic dermatitis: Section 1. Diagnosis and assessment of atopic dermatitis. *J Am Acad Dermatol*. 2014;70:338.
- Strachan DP. Hay fever, hygiene, and household size. *BMJ*. 1989;299:1249-1260.
- Leung DY, Boguniewicz M, Howell M, et al. New insights into atopic dermatitis. *J Clin Invest*. 2004;113:651-657.
- Kapoor R, Menon C, Hoffstad O, et al. The prevalence of atopic triad in children with physician-confirmed atopic dermatitis. *J Am Acad Dermatol*. 2008;58:68-73.
- Leung D, Bieber T. Atopic dermatitis. *Lancet*. 2003;361:151-160.
- Spergel J. From atopic dermatitis to asthma: the atopic march. *Ann Allergy Asthma Immunol*. 2010;105:99-106.
- Kabashima K. New concept of the pathogenesis of atopic dermatitis: Interplay among the barrier, allergy and pruritus as a trinity. *J Dermatol Sci*. 2013;70:3-11.
- Elias PM. Stratum corneum defensive functions: An integrated view. *J Invest Dermatol*. 2005;125:183-200.
- Elias PM, Steinhoff M. “Outside-to-inside” (and now back to “outside”) pathogenic mechanisms in atopic dermatitis. *J Invest Dermatol*. 2008;128:1067-1070.
- Koga C, Kabashima K, Shiraishi N, et al. Possible pathogenic role of $Th17$ cells for atopic dermatitis. *J Invest Dermatol*. 2008;128(11):2625-2630.
- Silverberg N, Silverberg J. Inside out or outside in: does atopic dermatitis disrupt barrier function or does disruption of barrier function trigger atopic dermatitis? *Cutis*. 2015;96:359-361.
- Hanifin J. Evolving concepts of pathogenesis in atopic dermatitis and other eczemas. *J Invest Dermatol*. 2009;129:320-322.
- Bos J, Kapsenberg M, Smitt J. Pathogenesis of atopic eczema. *Lancet*. 1994;343:1338-1341.
- Silverberg N, Lee-Wong M. Diet and atopic dermatitis. *Cutis*. 2016;97:227-232.
- Proksch E, Jensen J, Elias P. Skin lipids and epidermal differentiation in atopic dermatitis. *Clin Dermatol*. 2003;21:134-144.
- Cookson W. The immunogenetics of asthma and eczema: a new focus on the epithelium. *Nat Rev Immunol*. 2004;4:978-988.
- Sator P, Schmidt J, Honigsmann H. Comparison of epidermal hydration and skin surface lipids in healthy individuals and in patients with atopic dermatitis. *J Am Acad Dermatol*. 2003;48:352-358.
- Yoshiike T, Aikawa Y, Sindhananda J, et al. Skin barrier defect in atopic dermatitis: Increased permeability of the stratum corneum using dimethyl sulfoxide and theophylline. *J Dermatol Sci*. 1993;5:92-96.
- Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. *Nat Genet*. 2006;38:441-446.
- Weidinger S, Illig T, Baurecht H, et al. Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations. *J Allergy Clin Immunol*. 2006;118:214-219.
- Marenholz I, Nickel R, Ruschendorf F, et al. Filaggrin loss-of-function mutations predispose to phenotypes involved in the atopic march. *J Allergy Clin Immunol*. 2006;118:866-871.
- Sandilands A, Terron-Kwiatkowski A, Hull PR, et al. Comprehensive analysis of the gene encoding filaggrin uncovers prevalent and rare mutations in ichthyosis vulgaris and atopic eczema. *Nat Genet*. 2007;39:650-654.
- Scott IR, Harding CR. Filaggrin breakdown to water binding compounds during development of the rat stratum corneum is controlled by the water activity of the environment. *Dev Biol*. 1986;115:84-92.
- Sandilands A, Smith FJ, Irvine AD, et al. Filaggrin's fuller figure: A glimpse into the genetic architecture of atopic dermatitis. *J Invest Dermatol*. 2007;127:1282-1284.
- Howell MD, Kim BE, Gao P, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. *J Allergy Clin Immunol*. 2009;124:R7-R12.
- Liu X1, Beatty TH, Deindl P, et al. Associations between total serum IgE levels and the 6 potentially functional variants within the genes IL4, IL13, and IL4RA in German children: the German Multicenter Atopy Study. *J Allergy Clin Immunol*. 2003;112:382-388.

36. Mischke D, Korge B, Marenholz I, et al. Genes encoding structural proteins of epidermal cornification and S100 calcium-binding proteins form a gene complex ("epidermal differentiation complex") on human chromosome 1 q21. *J Invest Dermatol*. 1996;106:989-992.
37. Marenholz I, Zirra M, Fischer D, et al. Identification of human epidermal differentiation complex (EDC)-encoded genes by subtractive hybridization of entire YACs to a gridded keratinocyte cDNA library. *Genome Res*. 2001;11:341-535.
38. Hohl D, de Viragh P, Amiguet-Barras F, et al. The small proline-rich proteins constitute a multigene family of differentially regulated cornified cell envelope precursor proteins. *J Invest Dermatol*. 1995;105:902-904.
39. Marshall D, Hardman M, Nield K, et al. Differentially expressed late constituents of the epidermal cornified envelope. *Proc Natl Acad Sci U S A*. 2001;98:13031-13036.
40. Listwan P, Rothnagel J. Keratin bundling proteins. *Methods Cell Biol*. 2004;78:817-827.
41. Morar N, Willis-Owen S, Moffatt M, et al. The genetics of atopic dermatitis. *J Allergy Clin Immunol*. 2006;118:24-34.
42. Taylan F, Nilsson D, Asad S, et al. Whole-exome sequencing of Ethiopian patients with ichthyosis vulgaris and atopic dermatitis. *J Allergy Clin Immunol*. 2015;136(2):507-509. e19.
43. Miyai M, Hamada M, Moriguchi T, et al. Transcription factor *mafb* coordinates epidermal keratinocyte differentiation. *J Invest Dermatol*. 2016;136(9):1848-1857.
44. Zhang ZK, Yang Y, Bai SR, et al. Screening for key genes associated with atopic dermatitis with DNA microarrays. *Mol Med Rep*. 2014;9:1049-1055.
45. Marenholz I, Rivera V, Esparza-Gordillo J, et al. Association screening in the epidermal differentiation complex (EDC) identifies an *SPRR3* repeat number variant as a risk factor for eczema. *J Invest Dermatol*. 2011;131:1644-1649.
46. Mosmann T, Coffman R. TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties. *Annu Rev Immunol*. 1989;7:145-173.
47. Simpson E, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. *N Engl J Med*. 2016;375:2335-2348.
48. Honzke S, Wallmeyer L, Ostrowski A, et al. Influence of th2 cytokines on the cornified envelope, tight junction proteins, and beta-defensins in filaggrin-deficient skin equivalents. *J Invest Dermatol*. 2016;136(3):631-639.
49. Hanifin J. Atopic dermatitis. *Allergy*. 1988;43:36-38.
50. Novak N, Kruse S, Potreck J, et al. Single nucleotide polymorphisms of the *IL18* gene are associated with atopic eczema. *J Allergy Clin Immunol*. 2005;115:828-833.
51. Bieber T. Atopic dermatitis. *N Engl J Med*. 2008;358:1483-1494.
52. Bai B, Tanaka K, Tazawa T, et al. Association between RANTES promoter polymorphism-401 A and enhanced RANTES production in atopic dermatitis patients. *J Dermatol Sci*. 2005;39:189-191.
53. Novak N, Kraft S, Bieber T. Unraveling the mission of the FcεRI on antigen-presenting cells. *J Allergy Clin Immunol*. 2003;111:38-44.
54. Leung D, Guttman-Yassky E. Deciphering the complexities of atopic dermatitis: Shifting paradigms in treatment approaches. *Clin Rev Allergy Immunol*. 2014;134(4):769-779.
55. Howell MD, Gallo RL, Boguniewicz M, et al. Cytokine milieu of atopic dermatitis skin subverts the innate immune response to vaccinia virus. *Immunity*. 2006;24:341-348.
56. Trautmann A, Akdis M, Kleemann D, et al. T cell-mediated Fas-induced keratinocytes apoptosis plays a key pathogenic role in eczematous dermatitis. *J Clin Invest*. 2000;106:25-35.
57. Gittler J, Shemer A, Suarez-Farinas M, et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. *J Allergy Clin Immunol*. 2012;130:1344-1354.
58. Hijnen D, Bruijnzeel-Koomen C, Hack I, et al. Interleukin-13 and interferon-γ producing skin resident CD8+ T cells: A vicious circle of barrier disruption of the skin in atopic dermatitis. *J Invest Dermatol*. 2008;128:S1-S4. (abstract).
59. Hamid Q, Boguniewicz M, Leung DY. Differential in situ cytokine gene expression in acute versus chronic dermatitis. *J Clin Invest*. 1994;94:870-876.
60. Ong P, Takaaki O, Brandt C, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. *N Engl J Med*. 2002;347:1151-1160.
61. Howell M, Kim B, Gao P, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. *J Allergy Clin Immunol*. 2007;120:150-155.
62. Schlievert P, Strandberg K, Lin Y, et al. Secreted virulence factor comparison between methicillin-resistant and methicillin-sensitive *Staphylococcus aureus*, and its relevance to atopic dermatitis. *J Allergy Clin Immunol*. 2010;125:39-49.
63. Noh J, Shin J, Park C, et al. Thymic stromal lymphopoietin regulates eosinophil migration via phosphorylation of L-plastin in atopic dermatitis. *Exp Derm*. 2016;25:880-886.
64. Illi S, von Mutius E, Lau S, et al. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. *J Allergy Clin Immunol*. 2004;113:925-931.
65. Bieber T, de la Salle H, Wollenberg A, et al. Human epidermal Langerhans cells express the high affinity receptor for immunoglobulin E (Fc epsilon RI). *J Exp Med*. 1992;175:1285-1290.
66. Novak N, Bieber T, Kraft S. Immunoglobulin E-bearing antigen presenting cells in atopic dermatitis. *Curr Allergy Asthma Rep*. 2004;4:263-269.
67. Shreffler W, Castro R, Kucuk Z, et al. The major glycoprotein allergen from *Arachis hypogaea*, Ara h 1, is a ligand of dendritic cell-specific ICAM-grabbing nonintegrin and acts as a Th2 adjuvant in vitro. *J Immunol*. 2006;177:3677-3685.
68. Traidl-Hoffmann C, Mariani V, Hochrein H, et al. Pollen-associated phytoestrogens inhibit dendritic cell interleukin-12 production and augment T helper type 2 cell polarization. *J Exp Med*. 2005;201:627-636.
69. Soumelis V, Reche PA, Kanzler H, et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. *Nat Immunol*. 2002;3:673-680.
70. Boguniewicz M, Leung DY. Atopic dermatitis: A disease of altered skin barrier and immune dysregulation. *Immunol Rev*. 2011;242:233.